The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...
Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death ...
Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback